background
lower
procalcitonin
pct
concentr
associ
reduc
risk
bacteri
communityacquir
pneumonia
cap
adult
data
children
limit
method
analyz
serum
pct
concentr
children
hospit
radiograph
confirm
cap
enrol
center
diseas
control
prevent
etiolog
pneumonia
commun
epic
studi
blood
respiratori
specimen
test
use
multipl
pathogen
detect
method
typic
bacteria
eg
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
atyp
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
respiratori
virus
multivari
regress
use
assess
associ
pct
concentr
etiolog
sever
result
among
children
median
age
year
interquartil
rang
iqr
patient
typic
bacteria
higher
pct
concentr
n
median
iqr
ngml
atyp
bacteria
n
median
iqr
ngml
viral
pathogen
n
median
iqr
ngml
pathogen
detect
n
median
iqr
ngml
p
child
pct
ngml
typic
bacteria
detect
procalcitonin
ngml
featur
neg
predict
valu
confid
interv
ci
sensit
ci
specif
ci
identifi
children
without
typic
bacteri
cap
conclus
lower
pct
concentr
children
hospit
cap
associ
reduc
risk
typic
bacteri
detect
may
help
identifi
children
would
benefit
antibiot
treatment
respiratori
virus
common
agent
detect
children
communityacquir
pneumonia
cap
howev
exclus
bacteri
pneumonia
challeng
empir
antibiot
commonli
prescrib
prevent
overprescrib
antibiot
children
low
risk
bacteri
cap
assist
discontinu
empir
prescrib
therapi
rapid
reliabl
method
identifi
patient
would
valuabl
procalcitonin
pct
peptid
precursor
hormon
calcitonin
produc
c
cell
thyroid
gland
neuroendocrin
cell
lung
intestin
among
healthi
individu
serum
pct
concentr
low
undetect
ngml
howev
usual
increas
markedli
patient
confirm
bacteri
infect
adult
pct
concentr
use
guid
initi
durat
antibiot
therapi
patient
cap
result
studi
assess
clinic
util
pct
children
cap
conflict
earli
studi
limit
sensit
pct
assay
vari
etiolog
test
method
object
studi
assess
whether
serum
pct
concentr
associ
type
pathogen
detect
diseas
sever
larg
well
defin
cohort
children
hospit
radiograph
confirm
cap
unit
state
addit
sought
evalu
util
pediatricspecif
pct
threshold
reliabl
identifi
children
low
risk
bacteri
cap
caus
typic
pathogen
streptococcu
pneumonia
streptococcu
pyogen
haemophilu
influenza
staphylococcu
aureu
utah
monro
carrel
jr
children
hospit
vanderbilt
nashvil
tennesse
includ
epic
studi
multicent
populationbas
prospect
activ
surveil
studi
radiograph
confirm
cap
children
perform
januari
june
children
enrol
epic
studi
salt
lake
citi
nashvil
residu
sera
obtain
time
hospit
avail
studi
protocol
approv
institut
review
board
site
cdc
diagnost
test
use
epic
studi
previous
describ
brief
typic
bacteri
pathogen
defin
pneumonia
pyogen
h
influenza
aureu
specif
viridan
group
streptococci
gramneg
bacteria
detect
blood
highqual
endotrach
aspir
except
viridan
group
streptococci
bronchoalveolarlavag
specimen
pleural
fluid
cultur
whole
blood
pleural
fluid
polymeras
chain
reaction
pcr
atyp
bacteria
defin
chlamydophila
pneumonia
mycoplasma
pneumonia
detect
combin
nasopharyngealoropharyng
npop
swab
pcr
viral
pathogen
defin
adenoviru
coronaviru
human
metapneumoviru
hmpv
rhinoviru
influenza
viru
parainfluenza
viru
respiratori
syncyti
viru
rsv
detect
npop
swab
pcr
increas
agentspecif
antibodi
titer
acutephas
convalescentphas
serum
specimen
obtain
week
discharg
aforement
viru
except
coronaviru
rhinoviru
particip
classifi
categori
base
pathogen
detect
typic
bacteri
pathogen
withwithout
viral
andor
atyp
detect
atyp
bacteri
pathogen
withwithout
viral
detect
viral
pathogen
pathogen
detect
children
residu
sera
group
includ
analysi
random
sampl
children
residu
sera
group
includ
residu
sera
frozen
pct
test
perform
use
vida
brahm
pct
assay
marci
letoil
franc
assay
detect
rang
ngml
pct
test
perform
retrospect
procalcitonin
result
avail
treat
clinician
clinic
inform
avail
personnel
perform
pct
assay
examin
sever
outcom
measur
includ
intens
care
unit
icu
admiss
invas
mechan
ventil
parapneumon
empyema
total
hospit
length
stay
lo
empyema
defin
presenc
pleural
effus
drainag
chest
tube
surgic
procedur
laboratori
test
result
use
confirm
drain
pleural
fluid
truli
empyema
thu
proxi
definit
calcul
median
pct
valu
compar
group
use
mannwhitney
u
test
examin
discriminatori
perform
pct
use
cutoff
decis
algorithm
use
adult
cap
diagnost
test
measur
includ
sensit
specif
posit
neg
predict
valu
diagnost
likelihood
ratio
calcul
pct
cutoff
ngml
due
frequent
use
ngml
cutoff
adult
literatur
threshold
select
major
comparison
assess
discriminatori
power
pct
concentr
distinguish
patient
typic
bacteri
pathogen
detect
multivari
logist
regress
model
develop
depend
variabl
defin
presenc
absenc
typic
bacteri
detect
tenfold
crossvalid
perform
brief
involv
split
dataset
equal
partit
model
fit
use
partit
test
remain
partit
process
repeat
time
partit
test
exactli
model
result
averag
across
run
produc
singl
estim
receiv
oper
curv
roc
plot
also
develop
statist
analys
perform
use
r
r
foundat
statist
comput
vienna
austria
demograph
microbiolog
find
clinic
characterist
children
includ
analysi
shown
tabl
typic
bacteria
withwithout
viral
andor
atyp
bacteri
codetect
detect
children
atyp
bacteria
withwithout
viral
codetect
detect
children
virus
alon
detect
children
bacteri
detect
includ
blood
cultur
n
blood
pcr
n
pleural
fluid
cultur
pcr
n
bronchoalveolar
lavag
cultur
n
cultur
highqual
endotrach
aspir
n
number
sum
due
detect
multipl
method
pathogen
detect
children
sever
outcom
includ
icu
care
children
invas
mechan
ventil
children
parapneumon
empyema
children
children
receiv
inpati
antibiot
receiv
outpati
antibiot
children
includ
studi
like
typic
atyp
bacteri
pathogen
detect
empyema
admit
icu
less
like
pathogen
identifi
compar
children
enrol
epic
studi
includ
analysi
supplement
tabl
median
pct
concentr
higher
typic
bacteri
pathogen
detect
ngml
iqr
compar
atyp
bacteria
detect
ngml
iqr
viral
pathogen
detect
ngml
iqr
pathogen
detect
ngml
iqr
p
comparison
figur
procalcitonin
concentr
similar
children
typic
bacteri
infect
alon
n
median
ngml
iqr
compar
bacteri
viral
codetect
n
median
ngml
iqr
p
tabl
among
children
cohort
pct
concentr
ngml
none
typic
bacteri
pathogen
detect
tabl
children
pct
concentr
rang
ngml
typic
bacteri
pathogen
detect
contrast
children
pct
concentr
ngml
typic
bacteri
pathogen
detect
p
use
cutoff
ngml
sensit
pct
identif
children
typic
bacteri
cap
ci
specif
ci
posit
predict
valu
ci
neg
predict
valu
ci
tabl
lower
cutoff
ngml
increas
sensit
ci
decreas
specif
ci
posit
predict
valu
ci
howev
neg
predict
valu
ci
pct
concentr
ngml
associ
lower
odd
typic
bacteri
detect
odd
ratio
ci
associ
remain
adjust
pretreat
antibiot
base
inpati
administr
time
first
dose
time
symptom
onset
specimen
collect
age
detect
influenza
rsv
hmpv
adjust
ci
tabl
show
clinic
outcom
children
cap
stratifi
pct
concentr
median
pct
concentr
significantli
higher
children
admit
icu
ngml
assess
discriminatori
power
pct
concentr
identifi
children
without
typic
bacteri
pneumonia
roc
curv
construct
figur
area
curv
ci
diagnost
accuraci
pct
typic
bacteri
detect
shown
figur
discuss
evalu
associ
serum
pct
concentr
pathogen
detect
sever
within
larg
well
defin
cohort
hospit
children
radiograph
confirm
cap
use
comprehens
diagnost
pathogen
detect
procalcitonin
concentr
ngml
strongli
associ
decreas
likelihood
detect
typic
bacteria
decreas
diseas
sever
higher
serum
pct
concentr
associ
increas
likelihood
icu
admiss
empyema
increas
hospit
lo
associ
remain
control
age
detect
bacteri
pathogen
procalcitonin
concentr
ngml
high
neg
predict
valu
effect
exclud
typic
bacteri
cap
adult
studi
shown
correl
higher
pct
concentr
isol
typic
bacteri
pathogen
elev
serum
pct
concentr
strongli
associ
bacterem
cap
studi
children
less
conclus
two
pediatr
studi
sweden
found
limit
associ
pct
concentr
detect
pathogen
cap
howev
studi
shown
reason
correl
highest
level
bacterem
cap
limit
earlier
studi
includ
relianc
insensit
method
cultur
bacteri
serolog
etiolog
diagnosi
use
first
gener
pct
assay
detect
limit
ngml
rang
viral
pneumonia
mild
bacteri
diseas
distinguish
recent
studi
includ
use
pct
assay
improv
rang
combin
modern
method
pathogen
detect
studi
extend
prior
work
evalu
predict
valu
pct
cap
etiolog
use
highli
sensit
pct
assay
cohort
children
cap
extens
laboratori
test
includ
modern
molecular
method
procalcitonin
concentr
children
studi
pneumonia
c
pneumonia
infect
lower
seen
children
either
typic
bacteri
viral
cap
report
previou
studi
adult
children
infecti
diseas
societi
america
pediatr
infecti
diseas
societi
cap
guidelin
emphas
use
empir
antibiot
children
hospit
cap
deemphas
empir
therapi
atyp
bacteria
guidelin
recommend
test
pneumonia
use
macrolid
infect
document
test
strongli
suspect
test
avail
valu
routin
treatment
atyp
pathogen
remain
controversi
howev
mani
patient
particularli
requir
hospit
may
benefit
similar
studi
data
show
overlap
pct
valu
bacteri
viral
caus
cap
note
children
pct
concentr
ngml
viral
atyp
pathogen
detect
current
method
identifi
typic
bacteria
caus
nonbacterem
pneumonia
limit
children
pct
concentr
ngml
viral
atyp
pathogen
detect
certain
elev
pct
repres
undetect
bacteri
coinfect
studi
pct
concentr
ngml
consid
presumpt
evid
bacteri
cap
despit
overlap
high
end
pct
concentr
rang
howev
low
end
ngml
detect
typic
bacteri
pathogen
importantli
children
bacterialvir
codetect
elev
pct
concentr
actual
higher
statist
differ
children
bacteri
detect
alon
patient
typic
bacteria
detect
data
exclud
possibl
viral
coinfect
could
lower
pct
concentr
children
bacteri
coinfect
howev
data
suggest
low
pct
concentr
accur
identifi
children
extrem
low
risk
typic
bacteri
infect
furthermor
children
pct
concentr
ngml
typic
bacteri
pathogen
detect
tabl
although
pct
result
avail
clinician
children
receiv
antibiot
therapi
cap
none
readmit
healthcar
system
discharg
thu
role
identifi
bacteria
ill
children
uncertain
lower
pct
concentr
associ
less
sever
diseas
cohort
base
icu
admiss
parapneumon
empyema
hospit
lo
high
pct
associ
parapneumon
empyema
children
requir
drainag
procedur
pct
concentr
ngml
use
pct
biomark
guid
antibiot
therapi
investig
number
set
among
adult
includ
sepsi
acut
lower
respiratori
tract
infect
lrti
acut
exacerb
chronic
obstruct
pulmonari
diseas
pneumonia
adult
trial
pctbase
algorithm
lrti
proven
safe
result
signific
reduct
overal
antibiot
use
trial
use
similar
cutoff
patient
requir
antibiot
therapi
definit
pct
ng
ml
probabl
pct
ngml
probabl
pct
ngml
definit
pct
ngml
experi
clinic
trial
date
use
pctguid
antibiot
therapi
pediatr
cap
limit
suggest
procalcitonin
guidanc
reduc
antibiot
treatment
lower
respiratori
tract
infect
children
adolesc
propa
studi
includ
children
diagnos
lrti
cap
swiss
emerg
depart
children
random
receiv
therapi
base
pctguid
algorithm
similar
adult
algorithm
describ
follow
standard
clinic
guidelin
among
children
cap
pctguid
algorithm
signific
reduct
length
antibiot
therapi
vs
day
p
rate
antibiot
initi
similar
vs
group
esposito
et
al
enrol
children
uncompl
cap
random
trial
use
simpler
pct
algorithm
antibiot
administ
children
pct
concentr
ngml
start
antibiot
stop
pct
fell
ngml
control
treat
accord
italian
societi
pediatr
guidelin
recommend
antibiot
therapi
hospit
children
cap
clinic
cure
rate
equival
group
significantli
fewer
patient
pct
arm
start
antibiot
vs
overal
antibiot
durat
shorter
vs
day
p
pediatr
guidelin
current
emphas
antibiot
children
hospit
cap
even
though
confirm
bacteri
pneumonia
epic
studi
bacteri
pathogen
detect
children
cap
typic
bacteri
pathogen
yet
receiv
abbrevi
cap
communityacquir
pneumonia
pct
procalcitonin
point
estim
present
top
line
confid
interv
present
second
line
parenthes
confid
interv
deriv
use
continuitycorrect
efficientscor
method
potenti
limit
antibiot
use
children
optim
treatment
children
hospit
cap
reduc
unnecessari
potenti
harm
antibiot
use
clinician
like
need
integr
pct
predictor
outcom
rapid
etiolog
diagnosi
pattern
immun
respons
identifi
express
profil
may
ultim
replac
individu
biomark
differenti
viral
bacteri
mix
infect
studi
number
strength
includ
prospect
enrol
radiograph
confirm
pneumonia
comprehens
diagnost
test
also
sever
limit
children
enrol
epic
includ
studi
howev
children
typic
bacteria
detect
children
hospit
particip
studi
includ
despit
extens
test
children
cap
etiolog
determin
base
continu
difficulti
identifi
bacteri
caus
cap
possibl
children
without
typic
bacteri
pathogen
detect
infect
bacteria
particularli
high
pct
patient
studi
receiv
inpati
antibiot
includ
viral
pathogen
detect
may
hamper
bacteri
detect
mani
children
residu
serum
avail
pct
analysi
children
residu
serum
avail
frequent
admit
icu
epic
enrol
children
preval
bacteri
detect
sever
diseas
higher
studi
sampl
estim
posit
predict
valu
pct
characterist
may
higher
would
observ
entir
epic
cohort
pct
test
standard
care
serum
collect
occur
median
day
iqr
admiss
observ
correl
time
serum
collect
pct
concentr
overal
stratifi
etiolog
data
shown
final
studi
suggest
serial
test
increas
accuraci
correl
pct
concentr
etiolog
diagnosi
perform
serial
monitor
larg
cohort
prospect
enrol
children
strictli
defin
radiograph
confirm
cap
underw
extens
test
etiolog
pct
cutoff
ngml
accur
identifi
children
lower
risk
typic
bacteri
cap
find
suggest
pct
may
safe
incorpor
treatment
algorithm
children
cap
reduc
antibiot
administr
durat
implement
studi
clinic
trial
pctguid
therapi
could
significantli
improv
care
children
cap
decreas
use
unnecessari
antibiot
supplementari
materi
avail
journal
pediatr
infecti
diseas
societi
onlin
author
wish
dedic
paper
memori
chri
stockmann
phd
die
tragic
rock
climb
accid
juli
year
old
chri
brief
career
remark
mani
way
prolif
public
paper
author
peerreview
paper
first
author
includ
seven
publish
journal
pediatr
infecti
diseas
societi
skill
interest
wide
rang
focus
epidemiolog
prevent
infecti
diseas
antimicrobi
stewardship
pharmacolog
pharmacogenom
clinic
decis
support
advanc
statist
model
made
mani
contribut
health
children
research
chri
complet
master
scienc
clinic
investig
phd
pharmacolog
toxicolog
univers
utah
join
univers
utah
divis
pediatr
infecti
diseas
research
assist
professor
juli
chri
known
brillianc
passion
research
incred
product
even
warm
humbl
unpretenti
style
extraordinarili
gener
time
expertis
innumer
friend
collabor
within
univers
utah
center
diseas
control
prevent
across
countri
chri
also
passion
backcountri
skier
mountain
biker
hiker
canyon
rock
climber
depart
pediatr
univers
utah
creat
chri
stockmann
memori
scholarship
fund
honor
foster
career
brilliant
passion
scientist
dedic
care
children
inform
donat
fund
pleas
contact
denis
begu
univers
utah
develop
offic
email
denisebegu
hscutahedu
disclaim
view
express
articl
author
necessarili
repres
view
center
diseas
control
prevent
cdc
role
studi
design
data
collect
data
analysi
data
interpret
write
report
decis
submit
report
public
financi
support
support
etiolog
pneumonia
